In a post hoc subgroup analysis of the longest TD study to date (open-label extension, non-blinded)1,2

Rapid TD symptom control as early as 2 weeks* with sustained results observed through ~3 years in patients with mood disorders2,3

Mood Disorder Subgroup: AIMS Score Reduction in RIM-TD Study2,3

AIMS score reduction in patients with mood disorders over the long term. 7.1-point reduction vs baseline.

7.1-POINT REDUCTION

vs baseline

*Symptom control defined as change in AIMS total score as early as Week 2 in placebo-controlled studies.3

The mood disorder subgroup included patients with bipolar disorder and depression.2

Mean total dose.3

Growing percentage of patients with mood disorders achieved ≥50% AIMS score improvement over time2

Patients With ≥50% Reduction in AIMS Total Score2 AIMS score improvement in patients with mood disorders over the long term. AIMS score improvement in patients with mood disorders over the long term.

In a post hoc subgroup analysis of the longest TD study to date (open-label extension, non-blinded)1,2

Rapid TD symptom control as early as 2 weeks§ with sustained results observed through ~3 years in patients with schizophrenia2,3

Schizophrenia Subgroup||: AIMS Score Reduction in RIM-TD Study2,3

AIMS score reduction in patients with schizophrenia over the long term. 6.3-point reduction vs baseline.

§Symptom control defined as change in AIMS total score observed as early as Week 2 in placebo-controlled studies.3

||Schizophrenia subgroup included patients with schizophrenia and schizoaffective disorder.2

Mean total dose.3

Growing percentage of patients with schizophrenia achieved ≥50% AIMS score improvement over time2

Patients With ≥50% Reduction in AIMS Total Score2 AIMS score improvement in patients with schizophrenia over the long term. AIMS score improvement in patients with schizophrenia over the long term.

AIMS, Abnormal Involuntary Movement Scale; TD, tardive dyskinesia.


REFERENCES: 1. Marder SR, Singer C, Lindenmayer J-P, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol. 2019;39(6):620-627. 2. Hauser RA, Barkay H, Fernandez HH, et al. Effects of long-term deutetrabenazine treatment in patients with tardive dyskinesia and underlying psychiatric or mood disorders. Presented at: Psych Congress; October 29-November 1, 2021; San Antonio, TX. 3. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.